US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis
Sun Pharmaceutical Industries Ltd 路 Press Release 路 30 Oct 2026, 1:35 pm
US FDA Approves Sun Pharma's ILUMYA for Active Psoriatic Arthritis On 30th Oct'26, Sun Pharma announced that the US FDA approved its supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis (PsA). Supported by Phase 3 INSPIRE-1 and INSPIRE-2 trials, this approval expands ILUMYA's label beyond moderate-to-severe plaque psoriasis, targeting an estimated addressable population of ~2.4m Americans living with PsA. The IL-23 inhibitor is administered exclusively by healthcare providers, strengthening Sun Pharma's high-growth global innovative medicines portfolio, which currently accounts for ~20% of company sales.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting 路 05 Nov 2026
- Q2FY27 Earnings Call Transcript 路 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility 路 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... 路 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 路 01 Nov 2026
- Q2FY27- Investor Call Audio Recording 路 31 Oct 2026
- Board Meeting Outcome - Conclusion 路 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 路 30 Oct 2026
